Your session is about to expire
← Back to Search
CAR T-cell Therapy
Cohort 4 for Multiple Myeloma
Phase 1 & 2
Waitlist Available
Led By John A Lust, MD, PhD
Research Sponsored by Senesco Technologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 3 and 6, and monthly during a 24-week follow-up period
Awards & highlights
No Placebo-Only Group
Summary
The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.
Eligible Conditions
- Multiple Myeloma
- Mantle Cell Lymphoma
- Lymphoma
- Leukemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ weeks 3 and 6, and monthly during a 24-week follow-up period
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 3 and 6, and monthly during a 24-week follow-up period
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety and tolerability
Secondary study objectives
Explore tumor response
Profile of pharmacokinetics
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: Cohort 4Experimental Treatment1 Intervention
0.375 mg/kg
Group II: Cohort 3Experimental Treatment1 Intervention
0.2 mg/kg
Group III: Cohort 2Experimental Treatment1 Intervention
0.05 mg/kg
Group IV: Cohort 1Experimental Treatment1 Intervention
0.0125 mg/kg
Find a Location
Who is running the clinical trial?
Senesco Technologies, Inc.Lead Sponsor
John A Lust, MD, PhDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
60 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger